Stay updated on ABI-009 for Epilepsy: Clinical Trial

Sign up to get notified when there's something new on the ABI-009 for Epilepsy: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ABI-009 for Epilepsy: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:52:41.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the phase 1 study of ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE). This change may reflect new information related to the safety, tolerability, and potential efficacy of the medication in children with medically-refractory epilepsy who have failed epilepsy surgery.
    Difference
    0.1%
    Check dated 2024-06-06T14:26:30.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as a person's general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' now includes detailed inclusion and exclusion criteria for study participants.
    Difference
    44%
    Check dated 2024-05-22T21:13:50.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T23:21:41.000Z thumbnail image

Stay in the know with updates to ABI-009 for Epilepsy: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ABI-009 for Epilepsy: Clinical Trial page.